With actinic keratosis (AK) diagnoses on the rise, there is some good news for patients, with the FDA approval of expanded use of Almirall’s topical therapy Klisyri.
In this instalment of our week-by-week clinical trials round-up, we look at life sciences research and development announced during the week of 12th to 16th February, from early-stage onwar
Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to a durable ef
European life sciences investor Medicxi has bundled together six privately-held companies with dermatology medicines in development under a single drugmaker – called Alys
Almirall has taken another step forwards in the development of a digital approach to managing and treating dermatological conditions, forming a three-year alliance with Mi
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
